Related references
Note: Only part of the references are listed.Pirfenidone as a novel cardiac protective treatment
Alberto Aimo et al.
HEART FAILURE REVIEWS (2022)
Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis
Thomas C. L. Bracco Gartner et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)
Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with Preserved Ejection Fraction
Gavin A. Lewis et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2022)
Channelling the Force to Reprogram the Matrix: Mechanosensitive Ion Channels in Cardiac Fibroblasts
Leander Stewart et al.
CELLS (2021)
Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
Francesca Graziani et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Cardiac fibrosis models using human induced pluripotent stem cell-derived cardiac tissues allow anti-fibrotic drug screening in vitro
Hiroko Iseoka et al.
STEM CELL RESEARCH (2021)
Human cardiac fibrosis-on-a-chip model recapitulates disease hallmarks and can serve as a platform for drug testing
Olya Mastikhina et al.
BIOMATERIALS (2020)
Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence
Alberto Aimo et al.
PHARMACOLOGICAL RESEARCH (2020)
Cells of the adult human heart
Monika Litvinukova et al.
NATURE (2020)
Modelling genetic diseases for drug development: Hypertrophic cardiomyopathy
Lorenzo Santini et al.
PHARMACOLOGICAL RESEARCH (2020)
Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis
Lina Marcela Barranco-Garduno et al.
HELIYON (2020)
Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
Alessandro G. Fois et al.
ANTIOXIDANTS (2020)
Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial
Gavin A. Lewis et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure
Chandan K. Nagaraju et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Generation of Quiescent Cardiac Fibroblasts From Human Induced Pluripotent Stem Cells for In Vitro Modeling of Cardiac Fibrosis
Had Zhang et al.
CIRCULATION RESEARCH (2019)
Myofibroblast modulation of cardiac myocyte structure and function
Chandan K. Nagaraju et al.
SCIENTIFIC REPORTS (2019)
Angiotensin-II Drives Human Satellite Cells Toward Hypertrophy and Myofibroblast Trans-Differentiation by Two Independent Pathways
Annunziatina Laurino et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
An Improved Method of Maintaining Primary Murine Cardiac Fibroblasts in Two-Dimensional Cell Culture
Natalie M. Landry et al.
SCIENTIFIC REPORTS (2019)
The deployment of cell lineages that form the mammalian heart
Sigolene M. Meilhac et al.
NATURE REVIEWS CARDIOLOGY (2018)
Electrical coupling between ventricular myocytes and myofibroblasts in the infarcted mouse heart
Michael Rubart et al.
CARDIOVASCULAR RESEARCH (2018)
Cell-Specific Pathways Supporting Persistent Fibrosis in Heart Failure
Stephen D. Farris et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Redefining the identity of cardiac fibroblasts
Michelle D. Tallquist et al.
NATURE REVIEWS CARDIOLOGY (2017)
Topical Administration of Pirfenidone Increases Healing of Chronic Diabetic Foot Ulcers: A Randomized Crossover Study
Marcela Janka-Zires et al.
JOURNAL OF DIABETES RESEARCH (2016)
Pirfenidone exhibits cardioprotective effects by regulating myocardial fibrosis and vascular permeability in pressure-overloaded hearts
Kiyoshi Yamagami et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2015)
Rapamycin Attenuates Aldosterone-Induced Tubulointerstitial Inflammation and Fibrosis
Bin Wang et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
Fibrosis - A Common Pathway to Organ Injury and Failure
Don C. Rockey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Molecular basis of selective atrial fibrosis due to overexpression of transforming growth factor-1
Dolkun Rahmutula et al.
CARDIOVASCULAR RESEARCH (2013)
A TRP to cardiac fibroblast differentiation
Charles K. Thodeti et al.
CHANNELS (2013)
A TRPC6-Dependent Pathway for Myofibroblast Transdifferentiation and Wound Healing In Vivo
Jennifer Davis et al.
DEVELOPMENTAL CELL (2012)
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Thomas A. Wynn et al.
NATURE MEDICINE (2012)
Nitric Oxide/Reactive Oxygen Species Generation and Nitroso/Redox Imbalance in Heart Failure: From Molecular Mechanisms to Therapeutic Implications
Chiara Nediani et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
In Vitro Effects of Pirfenidone on Cardiac Fibroblasts: Proliferation, Myofibroblast Differentiation, Migration and Cytokine Secretion
Qiang Shi et al.
PLOS ONE (2011)
Cardiac Fibroblast to Myofibroblast Differentiation In Vivo and In Vitro: Expression of Focal Adhesion Components in Neonatal and Adult Rat Ventricular Myofibroblasts
Jon-Jon Santiago et al.
DEVELOPMENTAL DYNAMICS (2010)
Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias
Duy T. Nguyen et al.
HEART RHYTHM (2010)
The multifaceted role of pirfenidone and its novel targets
Jose Macias-Barragan et al.
FIBROGENESIS & TISSUE REPAIR (2010)
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults
C. M. Rubino et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2009)
Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction
Stefan Frantz et al.
BASIC RESEARCH IN CARDIOLOGY (2008)
Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation
Brett Burstein et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy chinese volunteers
Shaojun Shi et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
NADPH oxidase-dependent redox signaling in human heart failure: Relationship between the left and right ventricle
Chiara Nediani et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2007)
Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure
Ken W. Lee et al.
CIRCULATION (2006)
In vivo genetic ablation by Cre-mediated expression of diphtheria toxin fragment A
A Ivanova et al.
GENESIS (2005)
NAD(P)H oxidase 4 mediates transforming growth factor-β1-induced differentiation of cardiac fibroblasts into myofibroblasts
I Cucoranu et al.
CIRCULATION RESEARCH (2005)
Share Paper
